

23 November 2017

ASX Limited
20 Bridge Street
Sydney NSW 2000


COMPANY ANNOUNCEMENTS

RESULTS OF THE ANNUAL GENERAL MEETING OF MEMBERS

In accordance with Listing Rule 3.13.2, Cellmid Limited (**ASX: CDY**) advises that the resolutions put to the Annual General Meeting of Shareholders held on Thursday 23 November 2017 were passed by the requisite majority.

All resolutions were passed without a poll on a show of hands.

Please find attached the information required pursuant to Section 251AA of the Corporations Act 2001 (Cth) and Listing Rule 3.13.2.

End
Contact: Maria Halasz, CEO
T +612 9221 6830
 @mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lynamid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. Intellectual property pertaining to midkine is being exploited through wholly owned subsidiaries Lynamid and Kinera. Advangen, Cellmid's consumer health business, sells its FGF5 inhibitor hair growth products in Australia and Japan, and currently expanding distribution in other territories. For further information, please see www.cellmid.com.au, www.evolisproducts.com.au and www.evolisprofessional.com.

DISCLOSURE OF MEETING PROXY VOTES

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	PROXY'S DISCRETION	ABSTAIN	FOR	AGAINST	ABSTAIN
RESOLUTION 1 – REMUNERATION REPORT	S	311,963,550	235,789,258 (75.58%)	73,306,760 (23.50%)	2,867,532 (0.92%)	731,666	N/A	N/A	N/A
RESOLUTION 2 – RE-ELECTION OF DIRECTOR – DR EDWARD FINTAN WALTON	S	367,906,733	336,521,767 (91.47%)	20,537,434 (5.58%)	10,847,532 (2.95%)	361,508	N/A	N/A	N/A
RESOLUTION 3 – ELECTION OF DIRECTOR – DR MARTIN GEORGE CROSS	S	368,156,733	353,235,145 (95.95%)	3,994,056 (1.08%)	10,927,532 (2.97%)	111,508	N/A	N/A	N/A
RESOLUTION 4 – RATIFICATION OF PRIOR ISSUE OF ORDINARY SHARES UNDER PLACEMENT	S	368,078,241	291,993,084 (79.33%)	65,237,625 (17.72%)	10,847,532 (2.95%)	190,000	N/A	N/A	N/A
RESOLUTION 5 – APPOINTMENT OF AUDITOR	S	366,600,156	355,284,124 (96.91%)	468,500 (0.13%)	10,847,532 (2.96%)	1,668,085	N/A	N/A	N/A
RESOLUTION 6 – CONSOLIDATION OF SECURITIES	S	368,128,241	308,433,748 (83.78%)	56,831,961 (15.44%)	2,862,532 (0.78%)	140,000	N/A	N/A	N/A
RESOLUTION 7 – APPROVAL OF THE EMPLOYEE INCENTIVE PLAN	S	312,445,216	229,575,999 (73.48%)	79,942,685 (25.59%)	2,926,532 (0.94%)	250,000	N/A	N/A	N/A